Welcome to our dedicated page for Therapeutic Solutions Intl news (Ticker: TSOI), a resource for investors and traders seeking the latest updates and insights on Therapeutic Solutions Intl stock.
Therapeutic Solutions Intl Inc (TSOI) delivers cutting-edge therapeutic innovations through focused biomedical research and strategic industry partnerships. This news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and corporate initiatives.
Access real-time information about TSOI's progress in developing novel therapies, including clinical trial results, FDA submissions, and research collaborations. Our curated news collection simplifies tracking of the company's advancements in biotechnology and pharmaceutical development.
Key updates include progress reports on therapeutic pipelines, intellectual property developments, and financial performance announcements. All content undergoes strict verification to ensure alignment with regulatory standards and factual accuracy.
Bookmark this page for streamlined access to TSOI's latest scientific achievements and corporate news. Regularly updated information helps stakeholders make informed decisions based on verified company developments.
Therapeutic Solutions International (TSOI) announced new findings from its spin-off, Campbell Neurosciences, revealing that CampbellCell universal donor stem cells help alleviate schizophrenia symptoms in animal models by enhancing immune modulation and boosting brain-derived neurotrophic factors (BDNF). The research indicated increased interleukin-4 production, which helps counter inflammatory cytokines like interleukin-17. Dr. Thomas Ichim highlighted the ongoing development of a biomarker for suicidal ideations, while Timothy Dixon praised the innovative approach combining immunotherapy and regenerative medicine for mental health treatment.